{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Malignancies&page=2",
    "query": {
      "condition": "Pediatric Malignancies",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Malignancies&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T02:50:13.714Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02982941",
      "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma",
        "Rhabdomyosarcoma",
        "Osteosarcoma",
        "Ewing Sarcoma",
        "Wilms Tumor",
        "Desmoplastic Small Round Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Enoblituzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "1 Year to 35 Years"
      },
      "enrollment_count": 25,
      "start_date": "2016-12",
      "completion_date": "2019-05-22",
      "has_results": false,
      "last_update_posted_date": "2022-02-08",
      "last_synced_at": "2026-06-26T02:50:13.714Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Bethesda, Maryland • Philadelphia, Pennsylvania + 3 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02982941"
    },
    {
      "nct_id": "NCT01518400",
      "title": "LIFE Cancer Survivorship Database for Pediatric Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pediatric Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Children's Hospital Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5000,
      "start_date": "2009-02",
      "completion_date": "2050-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-06-26T02:50:13.714Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01518400"
    },
    {
      "nct_id": "NCT03876769",
      "title": "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-Cell Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "CTL019",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 121,
      "start_date": "2019-06-24",
      "completion_date": "2027-10-19",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-06-26T02:50:13.714Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03876769"
    },
    {
      "nct_id": "NCT03330197",
      "title": "A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pediatric Brain Tumor",
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "Ad-RTS-hIL-12",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oral Veledimex - Arm 1 (Pediatric Brain Tumor)",
          "type": "DRUG"
        },
        {
          "name": "Oral Veledimex - Arm 2 (DIPG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Alaunos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "0 Years to 21 Years"
      },
      "enrollment_count": 6,
      "start_date": "2017-09-26",
      "completion_date": "2021-09-10",
      "has_results": true,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-06-26T02:50:13.714Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03330197"
    },
    {
      "nct_id": "NCT05792566",
      "title": "ATOMIC Mobile App to Increase Physical Activity (PA) Levels in Survivors of Childhood Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pediatric Cancer"
      ],
      "interventions": [
        {
          "name": "Atomic app",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Connecticut Children's Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "10 Years to 30 Years"
      },
      "enrollment_count": 35,
      "start_date": "2023-06-12",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-06-26T02:50:13.714Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05792566"
    },
    {
      "nct_id": "NCT00923351",
      "title": "Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Sarcoma",
        "Rhabdomyosarcoma-Embryonal",
        "Rhabdomyosarcoma- Alveolar",
        "Neuroectodermal Tumors, Primitive, Peripheral"
      ],
      "interventions": [
        {
          "name": "Tumor Purged/CD25 Depleted Lymphocytes",
          "type": "DRUG"
        },
        {
          "name": "Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rhIL-7",
          "type": "DRUG"
        },
        {
          "name": "Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Months",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "19 Months to 35 Years"
      },
      "enrollment_count": 44,
      "start_date": "2007-06-02",
      "completion_date": "2018-05-15",
      "has_results": true,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-06-26T02:50:13.714Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923351"
    },
    {
      "nct_id": "NCT01853345",
      "title": "iCAT for Recurrent/Refractory/HR Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pediatric Solid Tumor",
        "Sarcoma",
        "Neuroblastoma",
        "Wilms Tumor"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 101,
      "start_date": "2012-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-02-10",
      "last_synced_at": "2026-06-26T02:50:13.714Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853345"
    },
    {
      "nct_id": "NCT05099003",
      "title": "A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 132,
      "start_date": "2022-05-31",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-06-26T02:50:13.714Z",
      "location_count": 109,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 91 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05099003"
    },
    {
      "nct_id": "NCT04225676",
      "title": "Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Tisagenlecleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 5,
      "start_date": "2020-10-19",
      "completion_date": "2021-10-19",
      "has_results": true,
      "last_update_posted_date": "2023-01-30",
      "last_synced_at": "2026-06-26T02:50:13.714Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Kansas City, Missouri + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04225676"
    },
    {
      "nct_id": "NCT03632317",
      "title": "A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma",
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "2 Years to 30 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-10",
      "completion_date": "2025-10",
      "has_results": false,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-06-26T02:50:13.714Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03632317"
    }
  ]
}